Anindya Sen

Company: Eli Lilly & Co.

Job title: Executive Director, Research & Development

Seminars:

Panel Discussion: Addressing Safety Concerns Associated with Viral & Nonviral Neurological Gene Therapies 5:00 pm

Considering safety and immunogenicity challenges associated with delivering viral gene therapies to the CNS Looking in to dose related toxicity when using a higher dose to ensure high efficacy Debating whether nonviral vectors pose more or less of a safety concern when delivering to the CNS than viral vectorsRead more

day: Conference Day One